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Summary
Purpose. Osteoarthritis (OA) is the most common joint
disorder in the elderly, causing significant pain which
negatively affects mobility and quality ol liie. The aim of
the study was to assess the effectiveness of ultrasound
Ímage-guided intra-articular injections of Hyalubrix@ com-
bined with exercise therapy in the treatment of hip os-
teoarthritis.
Methods. This was a single site, prospèctive, open-fabel,
Investigator-initiated study. Forty patients rilere enrolled
and received three ultrasound image.guided injections
of Hyalubrix@, 45 days apart, combined with three ses-
sions a week of physícal therapy (proprioceptive rehabil-
itation of the lower limbs; gait training; balance training)
up to a total of 30 sessions (10 weeks), starting from one
week after the first injection.
Results. The primary obiective was to achieve a lasting
reduction in OA symptoms related to pain during activi-
ty. During the course of the study the pain perceived by
the patient during activity dropped from a mean value of
6.94 cm to a mean value of 1.46 cm and showed a statis-
tically significant decrease from visit 1 compared to
baseline (p < 0.05) which was confirmed at all the subse-
quent time points. Significant improvements were also
observed in the evaluation of the secondary objectives:
hip disability; OA-related pain at rest; daily functioning
and NSAIDs intake.
Conclusions. Results from this study including 40 pa-
tients for a total of 65 treated hips demonstrate a signifi-
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cant improvement in OA-related pain, hip disability, and
patient's daily functioning as well as a reduction in
NSAIDS intake. Patients suffering from hip OA sèem to
benefil from the treatment wiih Hyalubrix@ injections
plus exercise therapy.
KEY WORDS: hip osteoafihrosts; viscosupplementation; hyaluronic acid:
physical therapy.
Introduction
Osteoarthritis (OA) is the most common type of arthritis and
the main cause of disability in the elderly population world-
wide. Hip OA is the second most frequent form of OA affect-
ing a large joint, and its prevalence ranges from 3 to 11% in
populations over 35 years old (1-3).
Risk factors include genetics, female gender, past trauma,
advancing age and obesity. Given that the number of people
aged 65 and over is expected to double by 2030 (4), along
with escalations in obesity and physical inactivity (5, 6), the
social and economic ìmpacl on society of OA-related disabili-
ty can also be expected to increase.
The main symptoms of hip OA are joint pain and stiffness
which can limit mobility, affect quality of life and may lead to
disability.
Treatment is aimed at reducing pain and stiffness, limiting
disease progression and improving mobility and quality of
life.
Both nonpharmacological and pharmacologic treatment op-
tions are available, including complementary and alternative
therapies and surgery, and many patients will be treated with
a combination of both 17).
A nonpharmacological approach is particularly important in
the elderly population due to the likelihood that medications
are already being prescribed for co-morbidities with the as-
sociated risk of toxicìty and polypharmacy (B).
Initial conservative recommendations ìnclude education, self-
management, weight loss and physical exercise (9). Exer-
cise is a core recommendation in all non-pharmacological
guidelines for the management of patients with knee or hip
OA as it focuses on strengthening muscles and improving
the range of motion and can also contribute to ameliorating
pain and function.
Nevertheless, physical therapy alone does not always pro-
vide sufficient pain relief and patients turn to pharmacologi-
cal solutions such as acetaminophen. nonsteroidal anti-in-
flammatory drugs (NSAlDs) and/or cyclo-oxygenase 2 (COX-
2) selective inhibitors. While effective in relieving pain and
reducing stilfness and swelling, the associated possible car-
diovascular, gastroìntestinal and renal toxicities (10-12)
mean caution should be exercised in prescribing these thera-
pies, particularly in lhe elderly population and alternative sol
lutions sought.
Another non-pharmacological option used for reducing pain
and maÌntaining hip mobility is viscosupplementation, the ad-
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The patient's tested leg is placed in a "figure - 4,'supine po-
sition, where the knee is flexed and the ankle is placed on
the opposite knee. The hip is placed in flexion, abduction,
and external rotation (which is where lhe name FABER
comes from). îhe examiner applies a posterrorly directed
force against the medial knee of the bent leg towards the
table top. A positive test occurs when groin pain or buttock
pain is produced. Due to forces going through the hip joint as
well, the patient may experience pain if the pathology is lo-
cated in the hip as well.
Patient daily functioning, specifically the activities of daily liv-
ing and mobility, was assessed during the study by the
Barthel Index and Lequesne Index.
The Barthel lndex is a questionnaìre consisting in 10 items
evaluating feeding, moving from wheelchair to beo ano re-
turn, groomìng, transferring to and from a toilet, bathing,
walking on a level surface, going up and down stairs, dress-
ing, continence of bowels and bladder and it is parlicularly
helpful in monitoring improvement in activities of daily living
over time.
The scores for each of the items are summed to create a to-
tal score. The higher the score the more "independent" the
patienl is. Independence means that the person neeos no
assistance wìth any part ol the task.
The Lequesne Index is a 1o-question survey given to pa-
tients with hip OA to investigate functional impairment. lt
consists in 5 questions pertaining to pain or discomfort, 1
question dealing with maximum distance walked, and 4
questions about activities of daily living. The total question-
naire is scored on a A to 24 scale. Lower scores indicate
there is less functìonal impairment.
At each study visit the patient was asked about the NSAIDs
intake since the previous visit. Intake was recorded in terms
of yes/no.
Sample size and statistical analysis
Sample size was decided a priori and fixed at 40 treated pa-
tients as this was an exploratory Investigator-rnitiated study
wjth no control group.
The Full Analysis Set. which included all subjects receiving
treatment (Hyalubrixo and exercise), was considered for the
statistical analysis pertormed on absolule values or on
changes from baseline, as applicable, and at a level of sig-
nificance adjusted for the number of comparisons. All com-
parisons were performed considering the Visil 0 as baseline.
Demographic data were calculated on the 40 enrolled patients,
descriptive and inferential statistics referred to coxarthrosis pa-
rameters were calculated on the 65 treated hips.
Descriptive statistics were produced at all time points. The
last patient assessment (105 days after last injection) was la-
belled as Tfinal.
To describe the subjects' condilions before treatment and
demographic data, summary statislics (mean, median, stan-
dard deviation, minimum and maximum) were calculated for
continuous variables and the number and percentage of
eventslpatients in each category provided for categorical da-
+-
Summary statistics (mean, median, standard deviation, mini-
mum and maximum or number and percentage of patients)
were calculated for performance variables al all lime points.
An analysis of variance for repeated measures was conduct-
ed on continuous variables to compare values at each time
14fì
point agalnst baseline; a McNeemar test was performed on
dichotomous variables to assess changes from baseline.
Analysis of variance for repeated measures was conducted
considering tìme, gender, age group, BMI group and hyper-
tension co-morbidity as factors.
Results
Forty patients were enrolled and performed the study in the
period from February 201 1 up to December 2012, for a total
of 65 hips trealed.
Ba sel i ne c ha racter i stic s
All 40 subjects consenting to parlicipate in the sludy and
treated with the study product attended all the study vìsits
and underwent 30 sessions of physical therapy. Among the
40 patients, 15 were treated ín one hip only, while 25 were
affected by bilateral coxarthrosis and received Hyalubrix,oi, in-
jections in both hips.
There was a slightly higher number of female participants
(58%). Included patients had a mean age of 61 years (s.d.
'1 1.0; range 38-81)and a BMI of between 25 and 35 in 59%
of cases. Almost all patìents (95%) were non-smokers. The
most frequent diseases affecting the patients at sludy entry
were hypertension (65%) and heart disease (28%).
The disease characteristics and hip osteoarthritis symptoms
at baseline are reported in Tables 1 and 2.
Clinical outcome
OA related pain
During the course of the study the pain perceived by the pa-
tient during activity dropped from a mean value of 6.94 cm
(s"d.2.053; range: 1-10) to a mean value of 1.46 cm (s.d.
.1 
.393; range 0-6). The decrease was statistically significant
from T1 compared to baseline (p < 0.05) and was confirmed
at all of the subsequent time points (p<0.001).
The analysis of the variance for repeated measures consid-
ering time, age group, BMI group and presence of hyperten-
Table 1 - Disease characteristics of the 65 lreated hips.
n (%)
Hip
Kellgren-Lau rence
Grade
Presence of
Hypolonia
Positive Test
NSAIDs ìntake
Monolateral
Bilateral
tl
ill
lva
Quadriceps
Gluteal
Thomas
FABER
Trendelenburg
YES
15 (23.1)
50 (76.e)
24 (36.9)
40 (61.s)
1 (1.5)
11 (16.9)
13 (20.0)
59 (90.8)
s9 (90.8)
46 (70.8)
39 (60.0)
a The one patienl with a Kellgren-Laurence grade of lV ìn one of
the two hips affected by OA received treatment with Hyalubrix{r as
the patient could not undergo surgery.
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Table 3 - Hip disabilily: range of molion - mean values al each time point
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baseline from T2 (p< 0.0125) that was maintained at subse-
quent study time points (p<0.001).
Similarly, the percentage of positive Trendelenburg Test cas-
es decreased from 717" at baseline ta 23"k at Tfinal. The
McNemar test showed a statistically significant difference
compared to baseline from T3 (p< 0.001) and was main-
iained at subsequent study time points.
The number of patients reporting paìn on the hip joint at the
FABER test decreased from T2, but became statìstically sig-
nificant after the third injection (T3 p< 0.001) and remained
significant at Tfinal (p< 0.001) when compared to baseline:
the percentage of patients previously positive to the test that
became negative were 72k at T3 and 82% at Tfinat.
The percentages of cases changing from a posilive test
(Faber, îhomas and Trendelenburg) at baseline to a nega-
tive test at the subsequenl time points are displayed in the
Figure 3.
Patient's Oaily tun
The mean Lequesne index value oî 12.9 (s.d. 4.2 164; range:
4.00 -19.50) at baseline progressively decreased to a mean
value of 5.5 (s.d. 2.5731: range:1.5-14.5) at Tfinal. The de-
crease was statistically significant at T1 compared to base-
line and was confirmed at all of the subsequent time points
150
(p<0.001).
During the course of the study an increase in the Barthel In-
dex at different study time points was observed: the mean
value of 92.27 (s.d. 6.481; range: 75-100) registered at
baseline increased up lo a mean value of 97.23 (s.d. 3.191;
range: 90-100) at Tfinal. The increase was statislically signit
icant from T2 compared to baseline and was confirmed at all
of the subsequent time points (p<0.001).
The changes from baseline observed after the first, second
and third injectìon and at the final time point are reported in
Table 4.
NSAIDS intake
At study entry more than half of the patients declared they
were taking NSAIDS to alleviate pain symptoms (60% of cas-
es).
At T3, 54% of the patients who had been taking NSAIDs be-
fore entering the study declared they had stopped intake and
at the final observation (Tfinal) the percentage, among those
patienls taking NSAIDs before entering the study, further in-
creased up to 55% (p<0.001 against baseline).
Safety
The trealment was well tolerated.
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first assessment vìsit (45 days). Following the two Hyalubrixq
injections and the compliance with the exercise program, the
patient became more independeni in the activities of daily
living leading to a significant improvement in muscular defi-
ciency and a reduction in NSAIDs intake shown after the
third Hyalubrix'o injection.
All these posilive effecls are still present at the final visit per-
formed 105 days after the last Hyalubrix6,injection.
Another strength of this study is the high patient compliance.
The intra-articular administration using Hyalubrix$ meansjust 3 iniectìons can be performed every 45 days rather than
more frequenlly as is the case wilh the 60 mg formulations
used in many other published studies. Pain is reduced from
the first injection and is maintained throughout the period,
ihus enabling optimal performance of the physical exercises
with consequent greater recovery of joìnt range of motion
and resolution of antalgic contractures and incorrecl posîure.
The efîect of the hyaluronic acid therefore enables the pa-
tient to comply better with the rehabilitation therapy, syner-
gising the two therapeutic eflects.
It could therefore be concluded that patients suffering from
hip OA seem to benefit from the treatment with Hyalubrixo,
injections plus exercise therapy; however a further controlled
study is indicated to evaluate the synergic effecl of the two
combined treatments.
Conflict of interest
îhe Authors declare that thev have no conflict of interest.
Ethical approval
All procedures performed in studìes involving human
participants were ìn accordance with the elhical standards of
îhe institutional and/or nalional research committee and with
the 1964 Helsinki declaration and its later amendments or
comparable ethical standards.
Informed consent
lnformed consent was obtaìned from all individual oarti-
cìpants ìncluded in the studv.
References
1. Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev.
'1988:10:1-28.
Ingvarsson T, Hagglund G, Lohmander LS. Prevalence of hip os-
teoarthritis ìn lceland. Ann Rheum Dis. 1999t58:201-207.
Floux C, Saraux A, lvlazieres B, Pouchol J, Morvan J, Fautrel B. et al.
KHOALA Osteoarlhritìs Group. Screening for hip and knee osteÒarthri-
ìis in the general populaîion: predictive value of a questionnaire and
prevalence estimates. Ann Rheum Dis. 2008;67:1406-141 1.
Nho SJ, Kymes SM, Callaghan JJ, Felson DT. The burden of hip os-
teoarthrÌtis in lhe United Statesi epidemiologic and economic consider-
ations, J Am Acad Orthop Surg.2013;21 Suppl 1:S1-6. doi: 10.5435/
JAAOS-21-07-S1 .
Felson DÎ. OsteoarthrÍtis: new insighls. Ann Intern Med. 20001'133:635-
646.
Yelin E, Murphy L, Cislernas MG, Foreman AJ, Pasta DJ, Helmick CG.
Medical care expenditures and earnings losses among persons wilh
arthrilìs and olher rheumatiÒ condìtions in 2003. and comparisons wtth
1 997. Arthritìs Rheum. 2007:56: 1 397 -1 407.
Dougados M, Hochberg li4C. lv4anagement of osteoarthritis. In: Hochberg
MC. Silman AJ, Smolen JS, Weinblatt L4E, WeismanM. editors. Rheuma-
tology. Sth ed. Philadelphia: Mosby/Elsevìer; 201 1 : p. 1 793-1 799.
Mushtaq S, ChoudharyR, Scanzello C- Non-surgìcal trealment of os-
leoarthritis-related pain in the elderly. Curr Rev Musculoskelet lvled.
2011,4 113-122.
Zhang W, Nuki G, l\loskowitz RW, et al. OARSI recommendations lor
the management of hìp and knee osteoarthrltis. Part lll: changes in
evìdence lollowing systematic cumulative update of research pub-
lashed through January 2009. Osteoarthritis and Cartìlage. 2010;
1 8:476-499.
Chan AT, Manson JE, Albert Cl\4, et al. Nonsteroìdal antiinflammatory
drugs. acetaminophen. and the risk of cardiovascular events. Cìrculation.
2006;1 1 3: 1 578-1 587. doi: 1 0.1 1 61 /Cl RCULATIONAHA.l 05.595793.
Rahme E, Barkun A, Nedjar H, et al. Hospìtalizations for upper and lower
Gl events associated with traditional NSAIDs and acetamìnophen among
îhe elderly in Quebec, Canada. Am J Gastroenterol. 2008;103:872-
882.
Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic
use and declìne in renal function in women. Arch Intern Med. 2004;164t
1519-1524.
Abate lvl, Scuccimarra T, Vanni D, et al. Femoroacetabular ìmpingement:
is hyaluronic acid effectíve? Knee Surg Sports Traumatol Arthrosc.
2014;22(4\:889-892.
lVigliore A, Bizzi E. Massafra U, et al. The impact of treaîment wilh hy-
lan G-F 20 on progression to total hip arthroplasty in patients with
symptomatic hìp OA: a retrospective study. Curr Med Res Opin.
201 2;28(5):755-760.
Migliore A, Massafra U, Bizzi E, et al, Infa-arlicular injection of hyaluronic
acid (MW 1,500 - 2,000 kDa; HyalOne) in symptomatic osleoarlhritis of
the hip: a prospeclive cohort study. Arch Orthop Trauma Surg.
201 1 ì1 31 (1 2):1 677-1 685.
Huang MH, Yang RC, Lee CL, Chen TW. Wang MC. Preliminary results
of integraîed therapy for palients with knee osteoarthritis. Arthritis
SRheum. 2005:53{6):81 2"820.
Bayramoglu M, Karataq M, Cetin N, Akman N, SÒzay S, Dilek A. Com-
parison of two ditferent viscosupplemenls in knee osteoarthritis 
- 
a pt-
lot study. clin Rheumarol. 2003 ;22(2J.1 1 I - 1 22.
Daniels L, Wonhingham C. Muscle Testing: Techniques of Manual Ex-
amination. 3rd ed. 1972. Philadelohia. Pa: WB Saunders Co.
c
4.
8.
10
1l
IJ
14.
tc,
to,
18
r52 Clinicaf Cases in Minefal and Bone Métabolism 2O17;1412):146-152
